Vistin Pharma ASA (OSL:VISTN)
Norway
· Delayed Price · Currency is NOK 21.60
+0.10 (0.47%)
At close: Mar 6, 2026
Vistin Pharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 452.29 | 429.09 | 435.39 | 287.68 | 275.81 | Upgrade
|
| Other Revenue | - | 0.41 | 2.94 | 17.18 | 2.81 | Upgrade
|
| Revenue | 452.29 | 429.5 | 438.33 | 304.85 | 278.62 | Upgrade
|
| Revenue Growth (YoY) | 5.31% | -2.01% | 43.78% | 9.41% | 9.74% | Upgrade
|
| Cost of Revenue | 151.51 | 149.97 | 176.64 | 138.06 | 96.1 | Upgrade
|
| Gross Profit | 300.78 | 279.53 | 261.68 | 166.79 | 182.53 | Upgrade
|
| Selling, General & Admin | 98.52 | 81.72 | 81.84 | 69.73 | 64.96 | Upgrade
|
| Other Operating Expenses | 87.38 | 93.49 | 93.9 | 90.88 | 73.71 | Upgrade
|
| Operating Expenses | 208.43 | 194.24 | 193.09 | 172.88 | 149.28 | Upgrade
|
| Operating Income | 92.35 | 85.3 | 68.6 | -6.1 | 33.25 | Upgrade
|
| Interest Expense | -11.02 | -2.34 | -2.27 | -2.14 | -0.36 | Upgrade
|
| Interest & Investment Income | 14.5 | 0.51 | 0.22 | 0.03 | 0.27 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -3.05 | -7.92 | 2.51 | -1.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | 0.04 | -0.11 | -0.31 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | 95.84 | 80.45 | 58.52 | -6.01 | 32 | Upgrade
|
| Pretax Income | 95.84 | 80.45 | 58.52 | -6.01 | 32 | Upgrade
|
| Income Tax Expense | 21.09 | 17.7 | 12.92 | -1.29 | 7.13 | Upgrade
|
| Earnings From Continuing Operations | 74.76 | 62.75 | 45.6 | -4.72 | 24.87 | Upgrade
|
| Net Income | 74.76 | 62.75 | 45.6 | -4.72 | 24.87 | Upgrade
|
| Net Income to Common | 74.76 | 62.75 | 45.6 | -4.72 | 24.87 | Upgrade
|
| Net Income Growth | 19.13% | 37.62% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | Upgrade
|
| EPS (Basic) | 1.69 | 1.42 | 1.03 | -0.11 | 0.56 | Upgrade
|
| EPS (Diluted) | 1.69 | 1.42 | 1.03 | -0.11 | 0.56 | Upgrade
|
| EPS Growth | 19.13% | 37.62% | - | - | - | Upgrade
|
| Free Cash Flow | 62.03 | 67.05 | 72.69 | -74.8 | -18.26 | Upgrade
|
| Free Cash Flow Per Share | 1.40 | 1.51 | 1.64 | -1.69 | -0.41 | Upgrade
|
| Dividend Per Share | 1.500 | 1.250 | 1.000 | 0.750 | 0.750 | Upgrade
|
| Dividend Growth | 20.00% | 25.00% | 33.33% | - | 50.00% | Upgrade
|
| Gross Margin | 66.50% | 65.08% | 59.70% | 54.71% | 65.51% | Upgrade
|
| Operating Margin | 20.42% | 19.86% | 15.65% | -2.00% | 11.93% | Upgrade
|
| Profit Margin | 16.53% | 14.61% | 10.40% | -1.55% | 8.92% | Upgrade
|
| Free Cash Flow Margin | 13.71% | 15.61% | 16.58% | -24.54% | -6.55% | Upgrade
|
| EBITDA | 114.89 | 103.27 | 84.89 | 5.33 | 42.79 | Upgrade
|
| EBITDA Margin | 25.40% | 24.04% | 19.37% | 1.75% | 15.36% | Upgrade
|
| D&A For EBITDA | 22.53 | 17.97 | 16.3 | 11.43 | 9.54 | Upgrade
|
| EBIT | 92.35 | 85.3 | 68.6 | -6.1 | 33.25 | Upgrade
|
| EBIT Margin | 20.42% | 19.86% | 15.65% | -2.00% | 11.93% | Upgrade
|
| Effective Tax Rate | 22.00% | 22.00% | 22.08% | - | 22.28% | Upgrade
|
| Revenue as Reported | - | 429.5 | 438.33 | 304.85 | 278.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.